top of page
Lecture 10: Anticoagulation Pharmacology, Use, and Reversal
Lisa M. Baumann-Kreuziger MD, MS
Presentation Date:
November 13, 2025
> For many decades, heparin was the only choice of parenteral, acute acting anticoagulant (introduced in 1937) and warfarin was the only choice for an oral anticoagulant (introduced in 1954).
> With the first introduction of Direct Oral Anticoagulants (DOAC) in 2010, the options for anticoagulation have become safer and more effective, but also more complex.
> In this presentation, we will review the Pharmacology, and Reversal of anticoagulants.
Lisa Baumann Kreuziger, MD, MS
Investigator, Blood Research Institute
Senior Medical Director, Versiti
Professor, Medical College of Wisconsin
lisakreuziger@versiti.org
Disclosures
> Research funding from Takeda, Sanofi, Veralox, and CSL Behring
> Consulting for HRSA Vaccine Injury Compensation Program
Andexanet Alfa
> A recombinant form of factor Xa
> Lacks catalytic and membrane-binding activity
> Retains the ability to bind factor Xa inhibitors & TFPI
Lu et al. Nat Med 2013 Apr;19(4):446-5. West J Emerg Med. 2016;17(3):264–270. open access at http://escholarship.org/uc/uciem_westjem
Starting in 2025, lectures are eligible for Continuing Education Credit.
Link for CE:
bottom of page